about
β(2) -adrenoceptor agonists: current and future directionDifferential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterolPositioning new pharmacotherapies for COPDCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseasePrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism.Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?Biochemical basis of asthma therapy.A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjectsThe beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro.Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.Arformoterol tartrate in the treatment of COPD.Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.Safe use of long-acting β-agonists: what have we learnt?Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?Pharmacological treatment of COPD.Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease.Inhaled long-acting muscarinic antagonists in chronic obstructive pulmonary disease.Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma.Long-acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease.Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes.Emerging drugs for chronic obstructive pulmonary disease.Emerging drugs for asthma.Future of chronic obstructive pulmonary disease management.An update on bronchodilators in Phase I and II clinical trials.The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations.Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.Foamy macrophage responses in the rat lung following exposure to inhaled pharmaceuticals: a simple, pragmatic approach for inhaled drug development.Beta-Adrenergic AgonistsLongitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease.The burden of lung disease: the need for stem cell therapy--a review series prologue.The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.[COPD-Management, a comprehensive review].Isothermal Microcalorimetry of Pressurized Systems II: Effect of Excipient and Water Ingress on Formulation Stability of Amorphous Glycopyrrolate
P2860
Q24604047-5523847F-A17C-4EE0-B23E-714DA92768D2Q26775244-C85C3BFE-23A2-4F3B-A909-59F024028A90Q26798659-4FA58988-243E-4EE4-BE26-24F1B84F9A91Q27012625-6C2ED36B-0B09-4F5D-82F1-817F9990C541Q27348844-0ADF2951-C355-4053-B761-421D8CE27AB0Q33792699-49C3412C-72E9-4438-A8BF-6A5C84A4A329Q35216188-B105E715-D81C-4368-BE42-A7946D56D3FCQ35312155-93C4E13C-0A72-4077-BDF3-6BCB85443590Q37635200-382870B2-163B-41D8-81FD-28E59CFB5036Q37661542-E8424054-EBBB-46BB-A0D1-C3ED5D444FE6Q37667100-E8344FA6-5FA1-4008-8E53-BB02F421FD06Q37734436-6C755F4E-FD8E-4D91-AA8B-EF42F6E13D19Q37762827-6E3AFF9C-9319-41F8-810E-9D763480F523Q37869146-161E1433-7F4A-4709-AA77-169D8B856065Q37895710-CD66C272-AFAD-4F76-909B-AC16634104C3Q37924598-537EE845-F7E9-4536-9DD1-68156D1B4C81Q37937549-B4AA3FA7-5911-4A7C-A6AB-2DAD606C6265Q37937554-1776C433-63B6-4A8B-B8D3-71915D4C60C0Q37937562-8CBF8333-9F16-4CCA-A8B6-EDFE5EC73639Q37960070-269C9BE8-2E14-4C63-AEFA-205C4DE11DCAQ37973657-F49F073A-F567-4523-8D34-BA4CEF21AE3FQ37984088-17F71ED3-AD0E-4FDF-9A2D-6A0985A02237Q38011270-20DC72E7-D3FD-4344-8400-1FD19956E2C6Q38025725-C63B2B00-4B8C-4F5D-A509-C465EEE64731Q38037123-514DB0DF-9BE8-41A0-A0A2-58CD8240579BQ38087697-AE533375-CFD9-42E5-8891-04E348B87656Q38107178-B5DAF3CE-76D7-4AA6-9EA3-12A4B2CB42C3Q38182903-12E68A92-89EF-4326-AB95-6D1F06780CBCQ38974241-3D387B77-0C40-486E-84B7-22FD470996AFQ39548676-29C3B358-1B75-486F-8F71-8E5F866F0472Q46483421-D3238FD1-9A5C-4B2C-B254-08DB89F20BD3Q51671642-BB3B5EC5-7BE8-4AFC-B39B-16D3CD652016Q51791945-58FAB3FE-60A7-4359-A07F-5D60F0E7ABDDQ59291755-1ED57DFA-CAB4-40D1-8776-EEEB98A01B0D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging inhaled bronchodilators: an update.
@en
Emerging inhaled bronchodilators: an update.
@nl
type
label
Emerging inhaled bronchodilators: an update.
@en
Emerging inhaled bronchodilators: an update.
@nl
prefLabel
Emerging inhaled bronchodilators: an update.
@en
Emerging inhaled bronchodilators: an update.
@nl
P1476
Emerging inhaled bronchodilators: an update.
@en
P2093
P304
P356
10.1183/09031936.00013109
P577
2009-09-01T00:00:00Z